Ken Griffin Medical Devices

Citadel Advisors LLC

$505 Billion
Q3 2024

Stock List

Stock	Market Cap.	Holding Value (Reported)	# of Shares.	Last Trade
BSX Boston Scientific Corp	$148B	$821 Million 0.16% of portfolio	9,793,103	Q3 2024 Reduced 21.65%
MDT Medtronic PLC	$120B	$524 Million 0.1% of portfolio	5,821,165	Q3 2024 Added 453.39%
ALGN Align Technology Inc	$16.9B	$395 Million 0.08% of portfolio	1,551,519	Q3 2024 Added 85.92%
PODD Insulet Corp	$19.4B	$231 Million 0.05% of portfolio	990,489	Q3 2024 Reduced 34.31%
EW Edwards Lifesciences Corp	$44.1B	$131 Million 0.03% of portfolio	1,991,503	Q3 2024 Added 218.95%
GMED Globus Medical Inc	$7.13B	$114 Million 0.02% of portfolio	1,586,624	Q3 2024 Added 103.33%
DXCM Dexcom Inc	$33.6B	$82.7 Million 0.02% of portfolio	1,233,844	Q3 2024 Added 69.51%
PEN Penumbra Inc	$10B	$80 Million 0.02% of portfolio	412,023	Q3 2024 Added 496.98%
ZBH Zimmer Biomet Holdings, Inc.	$22.7B	$52.3 Million 0.01% of portfolio	484,778	Q3 2024 Added 28.76%
GKOS Glaukos Corp	$7.43B	$46.8 Million 0.01% of portfolio	359,447	Q3 2024 Reduced 32.02%
ABT Abbott Laboratories	$225B	$41.2 Million 0.01% of portfolio	361,753	Q3 2024 Reduced 63.23%
LIVN Liva Nova PLC	$2.57B	$34.2 Million 0.01% of portfolio	651,756	Q3 2024 Reduced 58.34%
INSP Inspire Medical Systems, Inc.	$5.53B	$23.3 Million 0.0% of portfolio	110,311	Q3 2024 Added 248.52%
TNDM Tandem Diabetes Care Inc	$2.34B	$14.7 Million 0.0% of portfolio	347,823	Q3 2024 Reduced 80.77%
SYK Stryker Corp	$148B	$13.7 Million 0.0% of portfolio	37,882	Q3 2024 New
ZIMV Zim Vie Inc.	$361M	$12.1 Million 0.0% of portfolio	761,374	Q3 2024 Added 54.45%
AXNX Axonics, Inc.	$3.49B	$11.9 Million 0.0% of portfolio	170,323	Q3 2024 Added 672.02%
RXST Rx Sight, Inc.	$931M	$10.5 Million 0.0% of portfolio	211,743	Q3 2024 Added 66.09%
NARI Inari Medical, Inc.	$4.25B	$7.04 Million 0.0% of portfolio	170,757	Q3 2024 New
BIO Bio Rad Laboratories, Inc.	$8.7B	$6.86 Million 0.0% of portfolio	20,493	Q3 2024 New
INMD In Mode Ltd.	$1.38B	$5.36 Million 0.0% of portfolio	316,703	Q3 2024 Added 107.46%
ITGR Integer Holdings Corp	$4.58B	$5.29 Million 0.0% of portfolio	40,703	Q3 2024 Added 30.15%
ESTA Establishment Labs Holdings Inc.	$727M	$5.23 Million 0.0% of portfolio	120,933	Q3 2024 Reduced 31.85%
VREX Varex Imaging Corp	$544M	$4.9 Million 0.0% of portfolio	411,457	Q3 2024 Added 169.28%
OFIX Orthofix Medical Inc.	$364M	$4.49 Million 0.0% of portfolio	287,656	Q3 2024 Reduced 13.32%
AHCO Adapt Health Corp.	$1.38B	$4.27 Million 0.0% of portfolio	379,850	Q3 2024 Added 25.68%
IRTC I Rhythm Technologies, Inc.	$3.27B	$4.09 Million 0.0% of portfolio	55,046	Q3 2024 Reduced 66.47%
PRCT Procept Bio Robotics Corp	$3.18B	$3.49 Million 0.0% of portfolio	43,617	Q3 2024 Added 59.19%
BVS Bioventus Inc.	$647M	$3.21 Million 0.0% of portfolio	268,770	Q3 2024 Reduced 50.48%
NVRO Nevro Corp	$176M	$2.99 Million 0.0% of portfolio	536,060	Q3 2024 Added 114.38%
QTRX Quanterix Corp	$327M	$2.41 Million 0.0% of portfolio	186,085	Q3 2024 Reduced 20.73%
AVNS Avanos Medical, Inc.	$779M	$2.38 Million 0.0% of portfolio	98,932	Q3 2024 Reduced 54.5%
SNN Smith & Nephew PLC	$11B	$2.25 Million 0.0% of portfolio	72,211	Q3 2024 Reduced 62.57%
CERS Cerus Corp	$319M	$1.85 Million 0.0% of portfolio	1,061,991	Q3 2024 Added 221.21%
SIBN Si Bone, Inc.	$584M	$1.63 Million 0.0% of portfolio	116,596	Q3 2024 Reduced 25.71%
BRKR Bruker Corp	$8.4B	$1.58 Million 0.0% of portfolio	22,837	Q3 2024 Reduced 98.84%
BFLY Butterfly Network, Inc.	$686M	$1.57 Million 0.0% of portfolio	888,131	Q3 2024 Added 126.86%
CTKB Cytek Biosciences, Inc.	$726M	$1.5 Million 0.0% of portfolio	270,572	Q3 2024 Added 373.62%
DCTH Delcath Systems, Inc.	$134M	$1.39 Million 0.0% of portfolio	153,961	Q3 2024 Added 0.68%
KIDS Orthopediatrics Corp	$551M	$1.36 Million 0.0% of portfolio	50,101	Q3 2024 Added 19.77%
UFPT Ufp Technologies Inc	$2.05B	$1.1 Million 0.0% of portfolio	3,488	Q3 2024 Reduced 52.16%
ANIK Anika Therapeutics, Inc.	$252M	$1.04 Million 0.0% of portfolio	42,070	Q3 2024 Reduced 52.8%
CNMD Conmed Corp	$2.17B	$1.01 Million 0.0% of portfolio	14,097	Q3 2024 Reduced 94.09%
CLPT Clear Point Neuro, Inc.	$415M	$963,000 0.0% of portfolio	85,914	Q3 2024 Reduced 53.56%
ATEC Alphatec Holdings, Inc.	$1.2B	$961,000 0.0% of portfolio	172,542	Q3 2024 Reduced 25.31%
INGN Inogen Inc	$262M	$758,000 0.0% of portfolio	78,234	Q3 2024 Reduced 5.53%
PHG Koninklijke Philips Nv	$23.7B	$754,000 0.0% of portfolio	23,072	Q3 2024 Reduced 10.34%
MASS 908 Devices Inc.	$72.3M	$753,000 0.0% of portfolio	217,129	Q3 2024 Added 28.27%
SGHT Sight Sciences, Inc.	$131M	$722,000 0.0% of portfolio	114,700	Q3 2024 Added 14.97%
AORT Artivion, Inc.	$1.25B	$686,000 0.0% of portfolio	25,790	Q3 2024 Reduced 43.65%

Shares Options

Ken Griffin

Ken Griffin is the founder and CEO of Citadel Advisors, a successful investment firm that uses technology and data-driven approaches to investing. Griffin is known for his expertise in quantitative investing and his innovative approach to investing. He has generated strong returns for his clients over the long term.

Track Ken Griffin's portfolio

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account